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INTRODUCTION 
Starting in 1942, the United States Patent & Trademark Office 
(USPTO) has allowed patents to be issued for cannabis-related innovations.1 
                                                          
* Dawson Hahn, J.D. Candidate 2020, is a part-time Juris Doctorate Candidate at Concordia 
University School of Law, Editor-in-Chief of Concordia Law Review, and a full-time 
Software Engineer at Micron Technology, Inc. He would like to thank his friends and family 
for their support and motivation during the writing process. He would also like to thank 
Associate Dean Latonia Haney Keith and Associate Professor McKay Cunningham for their 
insight and guidance throughout his law school career. 
1 Eric Furman & Ari Feinstein, Patent Protection for Cannabis?, PHARMACEUTICAL 
EXECUTIVE (Nov. 13, 2018), http://www.pharmexec.com/patent-protection-cannabis. 
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Yet, the possession, cultivation, and distribution of marijuana has been 
outlawed since 1970 under the Controlled Substances Act (CSA).2 How can 
this be? This juxtaposition of cannabis and patents has led to many questions 
in the cannabis and intellectual property fields. Since there remains no 
legality requirement to secure a patent, the USPTO has been able to issue 
seemingly valid patents for cannabis and cannabis-related innovations. 
However, in bringing an infringement case for a cannabis-related patent, the 
patent owner is likely to detail activities that are currently illegal under 
federal law. How will that play out? Are these patents really valid? Will the 
federal courts enforce a cannabis-related patent? What kind of patent 
protections are available for a cannabis-related invention? These questions 
have gone unanswered so far because the courts have not heard a patent 
infringement case involving a cannabis-related patent. Until now. 
On July 30th, 2018, United Cannabis Corporation filed a complaint 
for patent infringement against Pure Hemp Collective, Inc. in the US District 
Court for the District of Colorado.3 Recreational cannabis use has been 
legalized in the state of Colorado,4 but patent infringement cases are a matter 
of federal law, where cannabis is still illegal.5 United Cannabis Corporation 
only asserted one patent in its complaint: U.S. Patent No. 9,730,911 (the ‘911 
Patent).6 The ‘911 Patent claims various liquid formulations of highly 
enriched extracts of plant cannabinoids and has seven independent claims.7 
As the CSA currently bans any “material, compound, mixture, or 
preparation” which contains any quantity of tetrahydrocannabinols or 
cannabimimetic agents, each of these claims describe a liquid formulation 
that would be illegal under federal law.8 In addition to United Cannabis 
Corporation’s suit, the Department of Justice and the Drug Enforcement 
Administration recently announced that Epidiolex, “the first FDA-approved 
drug made from the cannabis plant,” was reclassified as a Schedule V drug 
                                                          
2 See Controlled Substances Act, 21 U.S.C. § 812 (1970). 
3 Complaint for Patent Infringement and Demand for Jury Trial, United Cannabis Corp. v. 
Pure Hemp Collective, Inc., No. 1:18-cv-01922-NYW (D. Colo. 2017). 
4 COLO. REV. STAT. ANN. CONST. art. XVIII, § 16. 
5 21 U.S.C. § 812 Schedule I(c) (2012). 
6 Complaint for Patent Infringement and Demand for Jury Trial, United Cannabis (No. 1:18-
cv-01922-NYW). 
7 See U.S. Patent No. 9,730,911 (filed Oct. 21, 2015) (patenting the extraction of 
pharmaceutically active components from plant materials). 
8 Controlled Substances Act, § 812 Schedule I(c). 
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under the CSA.9 Does that mean that cannabis itself will soon be reclassified? 
That remains unclear. Since federal law still prohibits marijuana, any state 
laws that legalize marijuana seem to be at odds with federal law. While the 
10th Amendment protects a state’s ability to govern itself, the Supremacy 
Clause prevents state law from contradicting federal law.10 Thus, it seems 
like marijuana laws at the state level conflict with federal law unless 
marijuana is reclassified under federal law, which seems unlikely under the 
current administration.11 But maybe there’s another option. 
This Comment will examine the interactions of patent laws and 
cannabis laws in the United States. Section I sets forth a brief history of patent 
laws, while also detailing the requirements in obtaining a patent, and how one 
may infringe on a patent. Section II discusses the present status of cannabis-
related patents, introduces United Cannabis Corp. v. Pure Hemp Collective, 
Inc., and debates possible outcomes of the case. Section III debates the 
legality of cannabis in America and the impact of Federalism and the 
Supremacy Clause to state cannabis laws and proposes a solution to the 
dichotomy between state and federal cannabis laws. 
I. PATENT LAW OVERVIEW 
A.  The U.S. Patent System 
 Intellectual property can be thought of as “any product of the human 
intellect that the law protects from unauthorized use by others.”12 Intellectual 
property covers a large area of law, including patents, trademarks, copyrights, 
and trade secrets. Under Article I of the U.S. Constitution, Congress is given 
the power “[t]o promote the Progress of Science and useful Arts, by securing 
for limited Times to Authors and Inventors the exclusive Right to their 
respective Writings and Discoveries.”13 State and federal lawmakers have 
parlayed this enumeration into the federal Patent Act and federal Copyright 
Act, as well as other state and federal laws, which make up our basic 
                                                          
9 Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved 
Drugs Containing Cannabidiol, 83 Fed. Reg. 48,950 (Sept. 28, 2018). 
10 U.S. CONST. art. VI, cl. 2. 
11 See generally Memorandum from Attorney Gen. Jefferson B. Sessions, III to all United 
States Attorneys (Jan. 4, 2018) [hereinafter Sessions Memo] (available at 
https://www.justice.gov/opa/press-release/file/1022196/download). 
12 Intellectual Property, CORNELL LAW SCHOOL, 
https://www.law.cornell.edu/wex/intellectual_property (last visited Mar. 29, 2019). 
13 U.S. CONST. art. I. 
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intellectual property laws.14 Businesses, entities, and individuals all rely on 
intellectual property to further their economic goals. While each intellectual 
property right is significant in its own way, especially in the growing 
cannabis industry, this Comment focuses specifically on patents. 
Up until Congress passed the first federal Patent Act, patent 
protections were offered by state legislatures.15 Enacted in 1790, the first 
federal Patent Act was America’s first attempt at codifying the federal patent 
laws we have today.16 Since then, Congress has made significant changes to 
our federal patent laws, including a major overhaul of the Patent Act in 195217 
and the America Invents Act of 2011.18 While the original Patent Act has 
been modified and updated, many key terms and concepts from the 1790 Act 
have survived to the present day.19 Today’s federal Patent Act grants a 
patentee the right to exclude all others from making, using, offering for sale, 
and selling the patented invention within the United States, just as the 1790 
Act did.20  
Patent law helps promote progress in the sciences and the useful arts 
by giving inventors a limited right to exclude others from using their new 
inventions or methods without permission.21 Additionally, patent law helps 
accomplish two other important goals. First, the patent system helps to 
publicize inventions. Inventors must provide a written disclosure of their 
innovation which allows those skilled in the field to make and use the 
invention.22 This makes a public record of progress in the field of innovation 
and allows the general public to receive meaningful disclosure of new 
innovations.23 Second, patent laws help to reduce the risks of inadvertent 
disclosure and unprovable theft.24 As patent law does not require proof that 
an infringer directly copied or even knew of the patent in question, one who 
                                                          
14 LYDIA PALLAS LOREN & JOSEPH SCOTT MILLER, INTELLECTUAL PROPERTY LAW: CASES 
& MATERIALS 4–6 (6th ed. 2018). 
15 Herbert Hovenkamp, The Emergence of Classical American Patent Law, 58 ARIZ. L. REV. 
263, 267 (2016). 
16 Patent Act of 1790, Ch. 7, 1 Stat. 109–12 (amended 1793). 
17 Patent Act of 1952, Pub. L. No. 82-593, 66 Stat. 792 (1952). 
18 Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011). 
19 35 U.S.C. § 271 (2015). 
20 Id.; see also Patent Act of 1790 § 4. 
21 See LOREN & MILLER, supra note 14, at 125. 
22 35 U.S.C. § 111 (2015). 
23 See LOREN & MILLER, supra note 14, at 125. 
24 Colleen V. Chien, Opening the Patent System: Diffusionary Levers in Patent Law, 89 S. 
CAL. L. REV. 793, 818 (2016). 
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is using the invention disclosed in the patent without permission is liable for 
infringement.25 As a result, innovators that leverage the protections of patent 
law need not maintain secrecy from competitors or the public. This helps to 
strike a bargain between the public and the field of inventors to keep the 
nation abreast of new technologies, as well as granting protections to the 
inventors themselves; i.e., “fair notice for fair protection.”26 
B.  Obtaining a U.S. Patent 
 As patent prosecution is solely a matter of federal law, U.S. patents 
can only be granted by the U.S. Patent & Trademark Office (USPTO). There 
are a series of formal administrative processes that must be completed at the 
USPTO in order to obtain patent protection.27 Generally, the patent 
prosecution process begins when an inventor files an application for a 
patent.28 This application will describe the invention and enable a 
hypothetical “person skilled in the art” to make and use the invention.29 While 
the description is certainly an important aspect of the application, the most 
important part of the application are the claims specified. These claims state 
the subject matter that the inventor regards as her invention.30 More notably, 
these claims “state the legal boundaries of the products (or processes) that the 
patent owner can exclude others from making, using, selling, offering to sell, 
or importing into the U.S.”31 
 Filing an application is not the only obstacle a party needs to 
overcome in order to be granted a patent. A patent claim must be supported 
by the written disclosures in the application,32 in addition to meeting the 
substantive requirements of patent law. As codified in the United States 
Code, Section 101 of Title 35 details the functional requirements of a patent: 
“Whoever invents or discovers any new and useful process, machine, 
manufacture, or composition of matter, or any new and useful improvement 
                                                          
25 35 U.S.C. § 271(a) (2015). 
26 See LOREN & MILLER, supra note 14, at 126. 
27 35 U.S.C §§ 111–123 (2015). 
28 Id. § 111. 
29 Id. § 112(a); see also LOREN & MILLER, supra note 14, at 126–27 (“The application, if 
properly prepared, describes the invention and, through that description, enables the 
hypothetical person having ordinary skill in the art—often called the phosita—to make and 
use the invention.”). 
30 Id. § 112(b). 
31 See LOREN & MILLER, supra note 14, at 127. 
32 Id. 
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thereof, may obtain a patent therefor, subject to the conditions and 
requirements of this title.”33 These substantive requirements are broken down 
into four areas: patentable subject matter, utility, novelty, and 
nonobviousness.  
 In regards to patentable subject matter, the federal law seems clear 
that human intervention is key to three of the groups: machines, 
manufactures, and the composition of matters that do not occur naturally.34 
On the other hand, the Supreme Court has held that “[l]aws of nature, natural 
phenomena, and abstract ideas are not patentable.”35 However, at some level, 
all inventions use or apply laws of nature and abstract ideas, so the Court has 
pointed out that “a process is not unpatentable simply because it contains a 
law of nature or a mathematical algorithm.”36 Thus, the patentability of an 
invention or process falls upon whether the invention transforms the abstract 
idea into a “new and useful end.”37 The utility bar of Section 101 is not hard 
to meet—to be considered useful, an invention or process must be capable of 
providing some identifiable benefit.38  
 The novelty bar, which is codified in Section 102, can be more 
difficult to get past.39 Generally speaking, the novelty requirement allows for 
only new inventions to be patentable: “Congress may not authorize the 
issuance of patents whose effects are to remove existent knowledge from the 
public domain, or to restrict free access to materials already available.”40 
While out of the scope of this Comment, the framework for novelty currently 
exists in two different forms because of the changes made by the America 
Invents Act of 2011.41 The new Section 102 governs all patents whose 
applications were filed on or after March 16, 2013, and focuses on the filing 
data of the application, whereas the previous version of Section 102 focused 
                                                          
33 35 U.S.C § 101 (2015). 
34 See LOREN & MILLER, supra note 14, at 165 (“‘[M]achines’ and ‘manufactures’ are not 
found in nature, and naturally occurring materials are not ‘compos[ed]’”). 
35 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576, 589 (2013) 
(quoting Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66, 66 
(2012)). 
36 Parker v. Flook, 437 U.S. 584, 590 (1978). 
37 Id. at 591. 
38 Brenner v Manson, 383 U.S. 519, 534 (1966). 
39 35 U.S.C. § 102 (2015). 
40 Graham v. John Deere Co. of Kan. City, 383 U.S. 1,6 (1966). 
41 Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284, 285–86 (2011). 
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on the actual invention date.42 Finally, an invention must be nonobvious in 
order to obtain patent protections. Under Section 103, a claimed invention 
may be considered obvious “if the differences between the claimed invention 
and the prior art are such that the claimed invention as a whole would have 
been obvious before the effective filing date of the claimed invention to a 
person having ordinary skill in the art to which the claimed invention 
pertains.”43 If a claimed invention meets all of these substantive 
requirements—patentable subject matter, utility, novelty, and 
nonobviousness—it is then available for federal patent protections. 
C.  Patent Infringement 
In most cases, a patent, and the subsequent rights awarded by it, are 
in force from the date the patent was issued until 20 years from its original 
filing date.44 These rights given to the patentee protect the patent from being 
either directly or indirectly infringed upon. The Patent Act helps to define 
these rights by listing some activities that constitute infringement: “whoever 
without authority makes, uses, offers to sell, or sells any patented invention, 
within the United States or imports into the United States any patented 
invention during the term of the patent therefor, infringes the patent.”45 These 
five activities all have one thing in common—they are carried out by the 
accused infringer and they encompass every limitation (or element) described 
in the specified patent claim. This Comment focuses on direct infringement, 
which can be accomplished through literal infringement or nonliteral 
infringement.46 
Literal infringement occurs when each and every limitation of the 
claimed invention is present in another’s product or process.47 “One proves 
direct infringement by a mapping process of sorts, demonstrating that the 
defendant’s accused product or process meets every limitation of the claim 
considered individually.”48 In other words, the accused infringer’s product or 
                                                          
42 35 U.S.C. § 102. For a more detailed discussion of how the America Invents Act changes 
our patent system from first-to-invent to first-to-file, see Robert A. Armitage, Understanding 
the America Invents Act and its Implications for Patenting, 40 AIPLA Q. J. 1 (2012). 
43 35 U.S.C. § 103 (2015). 
44 35 U.S.C. § 154(a)(2) (2015). 
45 35 U.S.C. § 271(a) (2015). 
46 See LOREN & MILLER, supra note 14, at 262. 
47 Cybor Corp. v. FAS Technologies, Inc., 138 F.3d 1448, 1467 (Fed. Cir. 1998). 
48 See LOREN & MILLER, supra note 14, at 262. 
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process must contain or use every element defined in the patent claim to be 
considered direct infringement. For example, if a patent claim is for a widget 
X comprising sections A, B, and C, an inventor would directly infringe on 
the claim if she made widget Y comprised of sections A, B, and C. 
Additionally, if the inventor made a widget Z comprised of sections A, B, C, 
and D, this would also infringe upon the patent claim of widget X.49 In order 
to determine if there has been literal infringement, the court will use a two-
step test: “First, the claims are properly construed and then those construed 
terms are compared to the accused product.”50 That is to say, the court will 
first examine the claims to determine what is actually being claimed and then 
compare those claims to the unauthorized product or process. If the construed 
claims match the accused product, then there is literal infringement. 
Conversely, nonliteral infringement can occur when an unauthorized 
party’s product or process does not literally meet every limitation in a patent 
claim.51 This ideology is known as the doctrine of equivalents. As the Federal 
Circuit has noted, “[a] claim of infringement under the doctrine of equivalents 
modifies [the infringement analysis] . . . by requiring that the fact finder 
determine whether differences between particular elements of the accused 
device and the asserted claims are insubstantial.”52 For example, if a patent 
claimed the use of a laser pointer to be used for cat exercise, would an 
unauthorized party be infringing on that patent if they used a laser pointer to 
exercise their dog? The patent does not literally claim a dog, but a dog may 
be considered the equivalent of a cat. In order to determine whether an alleged 
equivalent is an insubstantial change, courts use the function/way/result 
test.53 This test looks at “whether the alleged equivalent performs 
substantially the same function, in substantially the same way, to achieve 
substantially the same result.”54 Using this test, courts can determine whether 
or not a product or process may nonliterally infringe upon a patent. Through 
these protections, patent holders are protected from the unauthorized use of 
                                                          
49 Cybor, 138 F.3d at 1467. 
50 University of Pittsburgh of Commonwealth System of Higher Educ. v. Varian Medical 
Sys., 561 Fed. Appx. 934, 942 (Fed. Cir. 2014). 
51 Cybor, 138 F.3d at 1467 
52 Id. 
53 See LOREN & MILLER, supra note 14, at 272. 
54 Id. 
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their invention, as well as the unauthorized use of an equivalent to the 
patented invention.55 
II. PATENT LAW AND CANNABIS 
 As discussed above, an invention or process must be new, useful, and 
nonobvious in order to be patentable.56 Additionally, the invention or process 
must be a patentable subject matter.57 But what if the subject matter is illegal 
or prohibited? What if the subject matter is seen as “immoral” by some 
people? While the Constitution and federal law do not specify a legality or 
“moral” requirement for patents, the courts have had some thoughts on the 
matter.58 
A.  Cannabis Patents 
 In his opinion in Lowell v. Lewis in 1817, Justice Story created the 
doctrine of “moral utility.”59 In Lowell, Justice Story heard a dispute 
regarding patent infringement on a water pump design, which seemed pretty 
standard on its face.60 However, Justice Story decided to use this clash to add 
a new condition to the patent utility requirement—an inventor must establish 
his invention as “new and useful,” not merely superior to current or 
previously existing iterations of a product.61 Additionally, Justice Story 
expanded that idea in an infamous passage: 
All that the law requires is, that the invention should not be 
frivolous or injurious to the well-being, good policy, or sound 
morals of society. The word ‘useful,’ therefore, is 
incorporated into the act in contradistinction to mischievous 
or immoral. For instance, a new invention to poison people, or 
to promote debauchery, or to facilitate private assassination, 
is not a patentable invention.62 
                                                          
55 Cybor, 138 F.3d at 1467. 
56 35 U.S.C. § 101 (2015). 
57 Id. 
58 See generally Lowell v. Lewis, 15 F. Cas. 1018 (Story, Circuit Justice, C.C.D. Mass. 1817) 
(creating the requirement of moral utility for patents); Juicy Whip, Inc. v. Orange Bang, Inc., 
185 F.3d 1364 (Fed. Cir. 1999) (dismissing Justice Story’s “moral utility” requirement). 
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This moral utility requirement influenced patent cases for the next century 
and half, protecting society from the moral evils of gambling gadgets63 and 
rakes,64 until the Federal Circuit dismissed Justice Story’s antiquated views 
in the 1999 case Juicy Whip, Inc. v. Orange Bang, Inc.65 
 The patent at issue in Juicy Whip was a “post-mix” beverage 
dispenser that kept beverage syrup concentrate and water in separate 
containers until the drink was ready to be dispensed.66 Conversely, a “pre-
mix” beverage dispenser stores syrup concentrate and water (that have 
already been mixed together) in a display reservoir bowl until it’s ready to be 
dispersed.67 The main point of contention in Juicy Whip was a fake display 
bowl used with the “post-mix” dispenser that created the illusion of the “pre-
mix” dispenser and led customers to believe that the “fluid contained in the 
bowl is the actual beverage that they are receiving.”68 While the “post-mix” 
beverage dispenser may deceive some customers, the Federal Circuit held 
that the patent was valid and that patents would no longer be denied based on 
the grounds of morality.69 The court reasoned that it was the place of the states 
to decide “by which the health, good order, peace and general welfare of the 
community are promoted,” and that patent laws were not intended to displace 
those state powers.70 Thus, the moral utility requirement in patent law was 
undone. While there may be some debate throughout the country on whether 
or not marijuana is “moral,” the outcome of that debate has no standing 
(anymore) on whether or not marijuana is patentable. 
 Further confirming the fact that the moral utility requirement is dead 
is the existence of the ‘507 patent, which is held by the U.S. Department of 
                                                          
63 See, e.g., Nat’l Automatic Device Corp. v. Lloyd, 40 F. 89 (C.C.N.D. Ill. 1889) (automatic 
toy racehorse used in gambling establishments); Reliance Novelty Co. v. Dworzek, 80 F. 
902 (C.C.N.D. Cal. 1897) (card-playing slot machine); Schultze v. Holtz, 82 F. 448 
(C.C.N.D. Cal. 1897) (coin return device for slot machine); Meyer v. Buckley Mfg. Co., 15 
F. Supp. 640 (N.D. Ill. 1936) (lottery ticket dispenser). 
64 See Fowler v. Swift, 3 Ind. 188 (1851) (finding the patent invalid because consumer was 
told rake was more efficient than other rakes). 
65 Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364 (Fed. Cir. 1999). 
66 Id. at 1365. 
67 Id. 
68 Id. at 1366. 
69 Id. at 1367 (“[Y]ears ago courts invalidated patents ... on the ground that they were 
immoral ... but that is no longer the law.”). 
70 Id. at 1368–69 (quoting Webber v. Virginia, 103 U.S. 344, 347–48 (1880)). 
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Health, and Human Services.71 That patent is currently being utilized by 
KannaLife Sciences, a late-stage biotechnology development firm, to 
develop new therapeutic agents with neuroprotectant and neuromodulation 
benefits through the use of medicinal cannabinoids.72 The company is 
currently working on research and development of a drug to treat Hepatic 
Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE), both 
of which are oxidative stress related diseases that affect the cognitive and 
behavioral functions of the brain, as well as the brain’s overall wellness.73 
While it is certainly ironic that the federal government denies any “accepted 
medical utility” for marijuana74 while simultaneously holding a patent for that 
same utility, the existence of the ‘507 patent highlights the value of marijuana 
patents and the need for medical research. The U.S. Patent and Trademark 
Office has issued over 500 cannabis-related patents since 2000, relating to 
strains of marijuana-related plants, chemical formulations, medical 
treatments, and devices used to make and/or consume marijuana products.75 
However, the true validity of these patents may be unknown.76 Due to the 
limited information available regarding prior inventions and questions as to 
what information is known in the cannabis industry, the patent office may be 
granting patents that are actually invalid.77 Additionally, the patent office 
may be allowing overly broad cannabis patents, which could result in patents 
that cover many strains and could stifle competition.78 Thanks to an 
upcoming case in the District of Colorado, we may get some answers to these 
validity questions. 
B.  United Cannabis Corp. v. Pure Hemp Collective, Inc. 
 On July 30th, 2018, United Cannabis Corporation (UCANN) filed a 
Complaint for Patent Infringement against Pure Hemp Collective, Inc. (Pure 
                                                          
71 U.S. Patent No. 6,630,507 (filed Feb. 2, 2001) (patenting cannabinoids as antioxidants and 
neuroprotectants as treatment for Alzheimer's, Parkinson's, HIV, dementia, and other 
progressive brain diseases). 
72 See generally The Company, KANNALIFE, https://www.kannalife.com/company (last 
visited Mar. 29, 2019). 
73 Id. 
74 21 U.S.C. § 812(b)(1), (c)(10) (2015). 
75 See Malathi Nayak, Cannabis Industry Seeks Clarity in Intellectual Property Haze 
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Hemp) in the U.S. District Court for the District of Colorado.79 Pure Hemp is 
a Colorado-based company that makes and sells plant-based remedies that 
combine hemp extract with natural blends of ingredients.80 UCANN is a 
biotechnology company in Golden, Colorado that is “dedicated to the 
development of phyto-therapeutic based products.”81 UCANN is suing Pure 
Hemp for infringing on its ‘911 Patent, which claims “various liquid 
formulations of highly enriched extracts of plant cannabinoids.”82 The ‘911 
Patent was issued to UCANN’s Chief Technologies Officer, Tony Verzura, 
and UCANN’s Chief Executive Officer, Earnie Blackmon, on August 15, 
2017.83 This patent is entitled “Cannabis extracts and methods of preparing 
and using same,” and it claims various liquid cannabinoid formulations, 
including those “wherein at least 95% of the total cannabinoids is cannabidiol 
(CBD).”84 UCANN claims in its suit that it purchased one of Pure Hemp’s 
5000mg products (Pure Hemp’s Vina Bell) and ran chemical composition 
tests on it to determine the cannabinoid formulations.85 According to 
UCANN, these tests revealed that Pure Hemp’s product contained a 
cannabinoid formulation wherein at least 95% of the total cannabinoids were 
CBD, which directly infringed upon one or more claims of the ‘911 Patent, 
specifically claim 10: “A liquid cannabinoid formulation, wherein at least 
95% of the total cannabinoids is cannabidiol (CBD).”86 Following this 
discovery, UCANN sent Pure Hemp a letter to inform Pure Hemp of their 
infringement on the ‘911 Patent and to offer a licensing agreement.87 
UCANN claims that Pure Hemp has continued to actively advertise, promote, 
and sell its infringing product, despite knowledge of the infringement.88 
 Pure Hemp has also filed an Answer to UCANN’s complaint 
(amended on November 5, 2018) in which Pure Hemp denies any 
                                                          
79 Complaint for Patent Infringement and Demand for Jury Trial, United Cannabis Corp. v. 
Pure Hemp Collective, Inc., No. 1:18-cv-01922-NYW (D. Colo. 2017). 
80 Our Legacy, PURE HEMP COLLECTIVE, https://purehempcollective.com/our-story/ (last 
visited Mar. 29, 2019). 
81 UCANN: UNITED CANNABIS, https://www.unitedcannabis.us/ (last visited Mar. 29, 
2019). 
82 Complaint for Patent Infringement and Demand for Jury Trial at 1, United Cannabis (No. 
1:18-cv-01922-NYW). 
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infringement on the ‘911 Patent.89 Specifically on the Willful Infringement 
claim, Pure Hemp “denies that it infringes or has infringed any valid, 
enforceable patent claim.”90 Pure Hemp’s answer claims that UCANN’s ‘911 
Patent is not valid because naturally occurring compounds (such as CBD) do 
not qualify as patentable subject matter due to the Supreme Court’s decision 
in Molecular Pathology v. Myriad Genetics.91 Not only does claim 10 of 
UCANN’s ‘911 Patent apply to isolated products of nature, but UCANN’s 
complaint also admits that cannabinoids “occur naturally in the cannabis 
plant.”92 Moreover, Pure Hemp claims that UCANN’s ‘911 Patent should not 
be valid because the ideas covered in it are not new.93 Citing studies and 
experiments from the 1940s,94 a U.S. Patent granted in 1942,95 and numerous 
pharmaceutical companies that have been selling CBD formulations that are 
at least 98% pure CBD since at least October 2011,96 Pure Hemp claims that 
the nearly pure CBD liquid compositions that are claimed in the ‘911 Patent 
are not new due to the fact that they were on sale and in use for years before 
the earliest priority date of the ‘911 Patent.97 
 In addition to the ‘911 Patent being invalid due to non-patentable 
subject matter and novelty, Pure Hemp claims that UCANN is attempting to 
monopolize the market for liquid CBD products, due to the extensive scope 
of the claims in the ‘911 Patent.98 Pure Hemp claims that:  
Claim 10 is so broad, in fact, that UCANN could likely 
attempt to assert it against (1) any farmer growing high-CBD 
chemovar cannabis who knows the cannabis will be used to 
make liquid formulations, (2) any midstream processor of 
high-CBD chemovar cannabis, (3) any producer of liquid 
                                                          
89 Defendant’s First Amended Answer, Defenses, and Counterclaims, United Cannabis Corp. 
v. Pure Hemp Collective, Inc., No. 1:18-cv-01922-NYW (D. Colo. 2017). 
90 Id. at 4. 
91 Id. at 9; Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013) 
(holding that claims directed to isolated, naturally occurring compounds do not qualify as 
patentable subject matter). 
92 Defendant’s First Amended Answer, Defenses, and Counterclaims, supra note 89, at 9. 
93 Id. 
94 Id. (“Pharmacological experiments with single cannabinoids have been carried out since 
the 1940s.”). 
95 Id. (“[T]he United States Patent Office granted U.S. Patent No. 2,304,669, titled Isolation 
of Cannabidiol.”). 
96 Id. at 8 (claiming that Echo Pharmaceuticals B.V., Tocris Bioscience, and Sigma-Aldrich 
have all been selling CBD formulations prior to the granting of UCANN’s ‘911 Patent). 
97 Id. at 9. 
98 Id. at 10. 
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CBD products, (4) any seller or reseller of liquid CBD 
products, (5) any purchaser of liquid CBD products, or (6) any 
user of liquid CBD products.99 
Thus, in addition to Pure Hemp’s affirmative defenses that the ‘911 Patent is 
invalid, Pure Hemp filed a counterclaim under the Sherman Act claiming that 
the ‘911 Patent would grant UCANN monopoly power over the liquid CBD 
product market.100 
 Not only has Pure Hemp filed its answer and counterclaim against 
UCANN, it also filed a motion for partial summary judgment on November 
29, 2018.101 Pure Hemp is requesting early partial summary judgment that 
claims 10, 12, 14, 20-22, 25, 27, 28, and 33 of the ‘911 Patent are invalid 
because they are “directed to patent-ineligible natural phenomena.”102 In Pure 
Hemp’s statement of facts, it claims that: (1) cannabis plants naturally contain 
differing quantities of cannabinoids; (2) cannabidiol (CBD), 
tetrahydrocannabinol (THC), and cannabinol (CBN) are cannabinoids that 
are found naturally in cannabis plants; (3) CBD and THC are the 
cannabinoids that are usually produced in the greatest abundance; (4) 
standard principles of pharmaceutical formulation can be used to prepare 
liquid dosage forms; (5) methods of computing cannabinoid content are well 
known to those skilled in the art; and (6) the Fourth Decennial Revision of 
the Pharmacopoeia of the United States of America, which was published in 
1864, provides directions for “preparing a liquid Tinctura Cannabis (or 
Tincture of Hemp) based on a Purified Extract of Hemp.”103 
 Using the framework set forth by the Supreme Court in Alice v. CLS 
Bank, Pure Hemp argues that the ‘911 Patent claims (specifically the claims 
that were mentioned earlier) are invalid because they fail to “contain an 
inventive concept sufficient to transform the claimed naturally occurring 
phenomena into a patent-eligible application.”104 The test from Alice is a two-
step test: (1) courts must “determine whether the claims at issue are directed 
                                                          
99 Id. at 10–11. 
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101 Defendant’s Early Motion for Partial Summary Judgment, United Cannabis Corp. v. Pure 
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to one of those patent-ineligible concepts;”105 and (2) if the answer to step 
one is “yes,” then the courts must ask: “[w]hat else is there in the claims 
before us?”106 Pure Hemp claims (and the ‘911 Patent agrees) that CBD, 
THC, and CBN are cannabinoids that are found naturally in the cannabis 
plant.107 Additionally, Pure Hemp claims that neither the liquid formulation 
limitation nor the “percent of total cannabinoid” limitation found in the ‘911 
Patent provide an inventive concept that would make the ‘911 Patent claims 
valid.108 Both of these limitations are routine and well-known to those skilled 
in the art, which is admitted in the ‘911 Patent. Thus Pure Hemp argues that 
claims 10, 12, 14, 20-22, 25, 27, 28, and 33 should not be valid since these 
claims are “directed to patent-ineligible natural phenomena without anything 
more that would constitute an eligible inventive concept.”109  
C.  Outlook After UCANN v. Pure Hemp 
 How this suit will play out is unknown at this time. What is known 
though, is that any outcome may have far-reaching consequences, due to the 
potential to set a precedent for how federal courts will handle marijuana-
related patents in the future.110 This case between UCANN and Pure Hemp 
is the first case involving a patent for a cannabis-based extract to reach the 
federal court system.111 Looking to Pure Hemp’s Answer and Motion for 
Partial Summary Judgment, it appears the court should invalidate the ‘911 
Patent, or at least the claims at issue in Pure Hemp’s motion. Validating the 
claims in the ‘911 Patent would likely give UCANN a monopoly over the 
liquid CBD market, as well as impede innovation in the CBD arena.112 While 
                                                          
105 See Alice Corp. Pty. v. CLS Bank Int’l, 134 S. Ct. 2347, 2355 (2014). The test in Alice is 
used for “distinguishing patents that claim laws of nature, natural phenomena, and abstract 
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that depends on other multiple dependent claims). 
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judges have addressed that “[i]t goes without saying that patents have adverse 
effects on competition”113 and “the essence of a patent grant is the right to 
exclude others from profiting by the patented invention,”114 patents are also 
supposed to drive innovation.115 
 Patent law attempts to strike a balance between seemingly competing 
areas by rewarding innovation without disproportionately impeding 
competition.116 As discussed earlier, a patent grants certain rights to the 
patent-holder, which allows her to exclude others from “making, using, 
offering for sale, or selling the invention” while the patent is valid.117 “But 
just as exclusion has always been the means, the diffusion of innovation has 
always been the desired end.”118 Unfortunately, when an invalid patent has 
been granted, the patent grants the same exclusionary rights to impede 
competition, but doesn’t grant the same reward to innovation. “This presents 
a problem because while our patent system attempts to strike a balance 
between encouraging innovation and suppressing competition, that balance 
is thrown off when an invalid patent issues. The invalid patent suppresses 
competition without enhancing innovation.”119 As Judge Learned Hand so 
aptly put, an invalid patent can be compared to a scarecrow—deterring 
competition and innovation even without doing anything.120 Not only can an 
invalid patent deter competition in the market, it can also impact attempts to 
improve on products. Competitors who are fearful of infringement litigation 
may decide not to invest in research and development in an area that is 
covered by an invalid patent or patents.121 This uncertainty in the scope of 
one’s intellectual property rights can lead to a chilling effect by leaving 
innovators unclear whether or not they are infringing upon a “pioneer’s 
intellectual property right.”122 Stifling technological advancement, regardless 
                                                          
113 In re Ciprofloxacin Hydrochloride Antitrust Litig., 363 F. Supp. 2d 514, 523 (E.D.N.Y. 
2005). 
114 Dawson Chem. Co. v. Rohm & Haas Co., 448 U.S. 176, 215 (1980). 
115 U.S. CONST. art. I (“To promote the Progress of Science and useful Arts . . . .”). 
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MINN. L. REV. 101, 114 (2006). 
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120 Bresnick v. U.S. Vitamin Corp., 139 F.2d 239, 242 (2d Cir. 1943). 
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of the field, harms consumers and harms society. Competitors who fear an 
infringement suit may attempt to innovate around a patent in order to create 
a non-infringing product or invention. Some judges view this process as a 
benefit of the patent system, but it’s often not an effective use of a limited 
research budget.123 “Other disputes arise because the set of potentially 
relevant patents is large, the scope of the claims is vague, and many of the 
claims might be invalid. Under these conditions, designing around patents is 
difficult and clearing the rights can be prohibitively expensive.”124 In short, 
when an invalid patent, or a patent with invalid claims, such as the ‘911 
Patent, is granted or upheld, innovation suffers.125 However, even if the ‘911 
Patent is invalidated, as long as cannabis is still illegal under federal law, 
innovation will naturally be hindered.  
III. FUTURE OF CANNABIS AND CANNABIS-RELATED PATENTS 
A.  Legality of Cannabis 
 Cannabis, more commonly known as marijuana, has had a 
distinguished history in America. Early settlers to America used the cannabis 
stalk to produce hemp: a multifaceted material that can be used to make 
numerous products such as clothing, paper, and rope.126 While the stalk of 
the cannabis plant was historically used as a material in manufacturing, the 
flower has had many medicinal, recreational, and spiritual uses through the 
years.127 In fact, the medicinal use of cannabis was recognized as providing 
enough medical benefits that cannabis was added to the United States 
Pharmacopeia in 1850 due to its remedial value.128 However, starting in the 
early 1900s, fear began to grow that the use of cannabis, as well as alcohol 
                                                          
123 State Indus., Inc. v. A.O. Smith Corp., 751 F.2d 1226, 1236 (Fed. Cir. 1985) (“One of the 
benefits of a patent system is its so-called ‘negative incentive’ to ‘design around’ a 
competitor's products, even when they are patented, thus bringing a steady flow of 
innovations to the marketplace.”); see also WMS Gaming, Inc. v. Int'l Game Tech., 184 F.3d 
1339, 1355 (Fed. Cir. 1999) (observing that “patent law encourages competitors to design or 
invent around existing patents”). 
124 Christopher R. Leslie, Antitrust and Patent Law as Component Parts of Innovation Policy, 
34 J. CORP. LAW. 1259, 1272 n.79 (2009). 
125 Id. at 161. 
126 Helia Garrido Hull, Lost in the Weeds of Pot Law: The Role of Legal Ethics in the 
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and opium, would lead to addiction, violence, and overdoses.129 By the time 
Congress passed the Marihuana Tax Act in 1937,130 every state in America 
had already enacted laws that criminalized the possession and sale of 
marijuana.131 The Marihuana Tax Act didn’t outlaw the possession or sale of 
marijuana, but it did require all buyers and sellers of marijuana to register 
with federal authorities and pay an annual tax.132 The extra work imposed by 
the Act, along with the aggressive fines and punishments,133 effectively led 
to a prohibition on cannabis, as shown by the removal of cannabis from the 
United States Pharmacopeia and other medical reference texts by 1942.134 
 After the Marihuana Tax Act was declared unconstitutional in 
1969,135 the Controlled Substances Act (“CSA”) was passed by Congress in 
1970 as a pseudo replacement.136 The CSA placed all controlled substances 
into five categories, or Schedules, based on the medicinal value, harmfulness, 
and potential for abuse.137 Because cannabis was effectively no longer being 
used for medicinal purposes, it was placed in Schedule I, which made it illegal 
for doctors to medically prescribe it.138 This means that cannabis is in the 
same category as heroin, ecstasy, and LSD because of a high potential for 
abuse, an absence of accepted medical utility, and a lack of accepted safety 
standards for cannabis use under medical supervision.139 Remarkably, opium, 
cocaine, and methamphetamine are categorized into a less restrictive 
Schedule than cannabis.140 There have been numerous petitions to the Drug 
Enforcement Agency (DEA) to reschedule marijuana.141 A 2002 petition 
requested that marijuana be removed from Schedule I because “cannabis has 
an accepted medical use in the United States, is safe for use under medical 
supervision, and has an abuse potential and a dependency liability that is 
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lower than Schedule I or II drugs.”142 As per CSA rescheduling provisions, 
the DEA requested a scientific and medical evaluation of marijuana from the 
Department of Health and Human Services (DHHS) after it received the 
petition.143 After completing the evaluation, the DHHS came to the 
determination that “marijuana has a high potential for abuse, has no accepted 
medical use in the United States, and lacks an acceptable level of safety for 
use even under medical supervision” and recommended that it remain in 
Schedule I.144 Thus, the DEA denied the petition and kept marijuana as a 
Schedule I drug, where it remains today.145  
 While cultivation, distribution, and possession of marijuana remains 
illegal under federal law, that hasn’t stopped a growing number of states from 
enacting marijuana-related laws of their own. In 2012, Colorado and 
Washington became the first two states to legalize recreational marijuana 
use.146 Since then, eight other states (as well as Washington, D.C.) have 
legalized the use of recreational marijuana for adults over the age of 21: 
Alaska, California, Maine, Massachusetts, Nevada, Oregon, Michigan, and 
Vermont.147 Additionally, 33 states have legalized marijuana for medical 
use.148 Even though these states are allowing marijuana use in their respective 
states, that doesn’t mean that it’s legal under federal law.  
B.  Federalism and the Supremacy Clause 
 There have been a few instances showcasing the ability of the federal 
government to regulate marijuana use in a state where marijuana has been 
legalized—notably in the 2005 Supreme Court case Gonzales v. Raich.149 In 
this case, the respondents included Monson, who was cultivating and 
consuming her own marijuana, and two California residents, who were using 
medical marijuana to treat serious medical conditions, as authorized under 
California’s medical marijuana statute.150 Despite concluding that Monson’s 
                                                          
142 Id. at 40,553. 
143 Id. at 40,566. 
144 Id. at 40,552. 
145 Id. 
146 See Jeremy Berke, Here's where you can legally consume marijuana in the US in 2018, 




149 See Gonzales v Raich, 545 U.S. 1 (2005). 
150 Id. at 6–7. 
2019 CONCORDIA LAW REVIEW 273 
 
use of marijuana was legal under California law, DEA agents and county 
deputy sheriffs raided Monson’s house and destroyed her marijuana plants 
under the authority of the CSA.151 Respondents sued the U.S. Attorney 
General and the head of the DEA, arguing that enforcement of the CSA 
prevented “them from possessing, obtaining, or manufacturing cannabis for 
their personal medical use” and violated “the Commerce Clause, the Due 
Process Clause of the Fifth Amendment, the Ninth and Tenth Amendments 
of the Constitution, and the doctrine of medical necessity.”152 The Supreme 
Court ultimately upheld the federal government’s authority to prohibit the use 
of marijuana, despite compliance with California law, since the CSA 
classifies cannabis as “contraband for any purpose.”153 The Court concluded 
that Congress has a “rational basis” for believing that the intrastate possession 
and manufacture of cannabis would “substantially affect interstate 
commerce,” and therefore was authorized in regulating its use under the 
Commerce Clause.154 The Court’s decision in Gonzales affirmed the federal 
government’s authority to regulate marijuana, but it did not restrict the ability 
of state governments to create their own marijuana laws, nor did the Court 
address whether Congress intended the CSA to preempt state medical 
marijuana statutes.155 
 While the U.S. Supreme Court has recognized Congress’s 
constitutional authority to pass the existing federal restrictions on marijuana, 
principles of federalism prevent the federal government from requiring that 
states actively support, or participate in, applying the federal law.156 The 
Tenth Amendment has been interpreted as protecting state sovereignty when 
the federal government’s Article I powers are limited.157 The Tenth 
Amendment prohibits the federal government from “commandeering” state 
government for federal purposes,158 or from “commandeering” state officers 
for purposes of carrying out federal law.159 Given these restrictions, Congress 
may not statutorily direct states to enact prohibitions on marijuana or repeal 
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existing exemptions for recreational or medical marijuana. Even though the 
federal government is prohibited from requiring states to adopt laws 
supportive of federal policy, preemption generally prevents states from 
creating laws that contradict federal law.160 The Supremacy Clause of the 
Constitution decrees that where state and federal laws are incompatible, 
federal law will preempt state law.161 There are three traditional categories of 
preemption (express preemption, conflict preemption, and field 
preemption),162 but there is a presupposition against preemption when it 
comes to the exercise of “historic police powers of the States.”163 While it 
would appear that a state law that permits an activity that is expressly 
prohibited by federal law would necessarily create an incompatibility 
between state and federal laws, the preemptive power of the CSA is limited 
by statute to situations where “there is a positive conflict between [the CSA] 
and that State law so that the two cannot consistently stand together.”164 As 
stated by Todd Garvey in a report prepared for members of Congress: 
Instead, the relationship between the federal ban on marijuana 
and state medical marijuana exemptions must be considered 
in the context of two distinct sovereigns, each enacting 
separate and independent criminal regimes with separate and 
independent enforcement mechanisms, in which certain 
conduct may be prohibited under one sovereign and not the 
other. Although state and federal marijuana laws may be 
“logically inconsistent,” a decision not to criminalize—or 
even to expressly decriminalize—conduct for purposes of the 
law within one sphere does nothing to alter the legality of that 
same conduct in the other sphere.165 
This preemption issue has yet to be addressed in federal court, but state courts 
have reached differing results on whether state programs issuing ID cards for 
medical marijuana users are preempted by federal law. In County of San 
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Diego v. San Diego NORML, a California appellate court found that the ID 
provisions of California’s medical marijuana law did not conflict with the 
CSA because the ID cards did not “insulate the bearer from federal laws.”166 
Conversely, in Emerald Steel Fabricators v. Bureau of Labor and Industries, 
the Oregon Supreme Court held that a state law issuing medical marijuana ID 
cards was preempted by the CSA.167 The Court reasoned that the law 
amounted to the state “[a]ffirmatively authorizing a use [for marijuana] that 
federal law prohibits,” and therefore the state law created an “obstacle” to the 
purposes of the CSA.168 
 There are significant preemption questions between the CSA and state 
marijuana laws that need to be answered. Under the Obama Administration, 
these preemption questions were not answered. While Obama was in office, 
the Department of Justice took a relaxed approach to enforcing federal 
marijuana laws as long as certain criteria were met.169 Through a 2013 memo 
written by former Deputy Attorney General James Cole, federal prosecutors 
were instructed to limit their investigations and resources to only watch for 
certain violations, such as distribution to minors or distribution across state 
lines.170 However, in January of 2018, former Attorney General Jeff Sessions 
issued a new memo that rescinded the Cole memo and instructed “all U.S. 
Attorneys to enforce the laws enacted by Congress and to follow well-
established principles when pursuing prosecutions related to marijuana 
activities.”171 While this move allows federal prosecutors to go after state-
legal marijuana at their own discretion, it still remains to be seen whether or 
not Session’s memo will lead to more marijuana prosecutions. While the use 
of Department of Justice memos as a defense to estop marijuana-related 
prosecution has not prevented prosecution,172 federal judges have used the 
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2013 Cole Memo as justification for lenient sentencing guidelines.173 As 
evidenced by current DOJ memos, the current Trump Administration has not 
adopted the same stance towards marijuana as the Obama Administration, but 
at this time, state marijuana laws remain in place and have not been 
preempted under the Supremacy Clause. 
C.  Cooperative Federalism 
 Change is likely coming to the marijuana laws in the United States, 
but what will these changes be? As stated earlier, more than half of the states 
have enacted state-level legislation aimed at legalizing some use for 
marijuana—either medical or recreational.174 While state legislators have 
kept up with the public support for marijuana, the federal government has 
been slow to react.175 Numerous federal marijuana-related bills have been 
introduced in Congress recently but none have gained much traction. 
Separately, these bills proposed to: (1) reschedule marijuana as a Schedule II 
drug and allow states to operate medical marijuana programs without federal 
interference;176 (2) end federal criminal penalties and civil asset forfeiture for 
individuals and businesses complying with state marijuana laws;177 (3) 
eliminate all federal marijuana crimes, except for shipping or transporting 
marijuana into a state where it is illegal;178 (4) legalize marijuana at the 
federal level and give oversight authority to the Bureau of Alcohol, Tobacco, 
Firearms and Explosives;179 and (5) federally legalize marijuana and impose 
a 25% excise tax on recreational marijuana sales.180 While there have been 
several opportunities for Congress to enact these laws or some version of 
them, Congress does not appear inclined to end or curtail the federal 
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prohibition of marijuana. Since a complete end of marijuana prohibition or a 
rescheduling under the CSA seem unlikely (especially under the current 
administration), a federal approach that cooperates with state law could be a 
realistic alternative. 
 Cooperative federalism has been described as “a partnership between 
the States and the Federal Government, animated by a shared objective.”181 
In other words, cooperative federalism permits state and federal laws to work 
together towards a group solution, instead of conflicting with each other.182 
Using this approach, Congress could amend the CSA to allow states to opt of 
out its regulations, provided that they enact state law that meets certain 
criteria or requirements. If states choose not to enact their own marijuana-
related laws, the state would still be governed by CSA regulations. This 
approach can already been found in several federal statutes, including the 
Clean Water Act183 and the Clean Air Act.184 Under the Clean Water Act, 
states are granted primary responsibility for water quality standards, but the 
federal government is permitted to take a more active role if the state fails to 
adhere to Environmental Protection Agency (EPA) mandates.185 Similarly, 
under the Clean Air Act, each state has the primary responsibility for the air 
quality and pollution within its geographic area.186 States are permitted to 
enact and carry out their own air pollution prevention plans, as long as those 
plans meet the requirements of the Clean Air Act.187 If the state plans do not 
meet the requirements of the Clean Air Act, then the federal plan will be put 
into place instead.188 Both the Clean Air Act and the Clean Water Act express 
congressional intent to have state and federal governments work together to 
prevent pollution, but neither Act requires state action.189 States may choose 
to do nothing and be subject to federal regulation, or they may choose to enact 
their own regulations. 
 Amending the CSA to allow state and federal governments to enforce 
and regulate marijuana together, rather than contradicting one another, would 
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allow the federal government to influence marijuana regulations while 
allowing states to independently enact their own state laws.190 “Federal law 
would supplement state law only when states defer to federal law or fail to 
satisfy federal requirements. Just as the EPA works with states to enforce air 
and water pollution laws, federal agencies could continue to cooperate with 
opt-out states and local governments to enforce marijuana laws.”191 This 
approach would give the federal government influence over regulatory 
priorities of the states that decide to craft their own legislation.192 Notably, 
this approach (or similar approaches) have been proposed by several 
prominent scholars as a “politically viable middle ground.”193 However, most 
of those scholars propose state-opt-out-plans that would allow states to 
completely legalize marijuana use (as long as certain federal priorities are 
met).194 This Comment proposes that a cooperative federalism approach 
should be used to promulgate the usage of marijuana in the medical and 
research fields. Under this approach, states would be able to opt out of the 
CSA if they enacted laws that regulated marijuana in the medical field or for 
research purposes. Similarly, this modification to the CSA would effectively 
legalize medical marijuana and legalize the use of marijuana for research 
purposes in all states that do not (or choose not to) enact their own state laws 
regarding marijuana. Utilizing this approach would be a safe middle ground 
between full decriminalization and full federal regulation, and would allow 
research and medical testing to continue (or begin) without worries of federal 
or state prosecution. Allowing unfettered access for researching and medical 
testing would take away much of the uncertainty and unknowns in the 
marijuana field. 
 Additionally, there would certainly be value in a standard regulatory 
framework that communicates the strain, THC, or CBD levels, as well as 
other important characteristics, given the number of different marijuana 
strains in existence.195 
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The primary obstacle in administering marijuana in medicine, 
however, is the uncertainty that currently undergirds medical 
marijuana strains at legal dispensaries. Certain strains are 
higher in the chemicals that are beneficial for chronic pain or 
other therapeutic qualities which don't get users high. Many 
patients who seek treatment with marijuana when traditional 
pharmaceuticals don't adequately address their medical needs 
don't want to be stoned, and they face difficulties in obtaining 
consistent inventory.196 
Freeing medical professionals and researchers from the threat of federal 
prosecution will allow for less uncertainty in the marijuana market and lead 
to more advances in medicine and genetic studies.197 As we stand right now, 
with the illegality of marijuana creating a void of scientific research, 
researchers and organizations have come to wide-ranging conclusions 
regarding the effects of marijuana. Some researchers claim that marijuana has 
been shown to have a wide range of useful medical properties, so it should 
not be classified as a Schedule I substance.198 On the other side of the map, 
some researchers have claimed that marijuana is dangerously addictive.199 
Furthermore, based on a study funded by the National Institute of Drug Abuse 
(NIDA), one group has claimed that “chronic marijuana use causes the frontal 
cortex of the brain to shrink.”200 Regardless of the differing opinions on 
marijuana use, gaps in cannabis research will continue to exist until standards 
and clinical trials are accepted and used. 
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 While there may be fears of the potential aftermath of any federal 
marijuana legalization, we can look at our neighbors to the North as a possible 
signpost of what to expect.201 While recreational use of marijuana in Canada 
is now permitted, marijuana used to be federally prohibited through the 
Controlled Drugs and Substances Act.202 However, in 2001, Canada enacted 
the Marihuana Medical Access Regulations (MMAR) which authorized 
possession of dried marijuana “for the medical purpose of the holder.”203 
MMAR allowed Canadian residents over the age of 18 to possess medical 
marijuana if they had authorization from the Minister, and it allowed 
residents to manufacture marijuana if they had the proper license to 
produce.204 Following the MMAR, the Canadian Parliament passed a new set 
of medical marijuana regulations in 2013: the Marihuana for Medical 
Purposes Regulations (MMPR).205 These new regulations resulted in the 
termination of the prior MMAR and shifted medical marijuana production 
away from personal growers towards corporate production of medical 
marijuana.206 Because of these new regulations, the Canadian medical 
marijuana industry experienced a shift towards a commercial model, which 
is similar to the heavily regulated prescription drug retailers.207 While Canada 
has now legalized recreational marijuana,208 America can look to the previous 
enactments of MMAR and MMPR as policies to learn from. 
D.  Patent Innovation 
 While legalizing marijuana at the state level is a step in the right 
direction, innovation that is available through patent protections does not 
amount to much when federal enforcement actions are still possible. Despite 
the fact that the USPTO has issued patents for marijuana-related inventions 
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and processes—as evidenced by the ‘911 Patent—there are still concerns 
among inventors and patent attorneys due to the federal illegality of 
marijuana.209 
First, some of the inventions can be used only for illegal 
purposes under federal law. Specifically, inventions 
particularly designed to be used in association with marijuana, 
and that can only be used for such purpose, would only be 
useful for illegal purposes. Nonetheless, some of the 
inventions can be used outside the marijuana industry. 
Second, the subject matter of some marijuana-related 
inventions is illegal; meaning the invention itself is illegal. 
Finally, in some cases, the application claims illegal subject 
matter and practicing the invention is illegal.210 
Specifically in regards to the application itself, there are risks involved in 
merely filing the application. As part of an application an inventor must 
describe the invention or process in detail and provide enough information to 
enable the invention, which could provide a federal prosecutor with a 
significant amount of evidence of a CSA violation.211 This risk also extends 
to patent attorneys. Aiding a marijuana business in its business affairs, such 
as applying for a patent, could be deemed a violation of the CSA and a case 
of professional misconduct.212 Thus, it seems expected that there would be a 
natural hesitation in pursuing and defending marijuana-related patents. 
Additionally, even if business does secure a marijuana patent, that patent may 
end up giving an imagined benefit to the patent holder. While the outcome of 
UCANN v. PureHemp may help to exemplify what benefits are afforded to 
marijuana patent holders, the fact remains that the risk will continue to exist 
as long as marijuana is illegal under federal law. “Even though it theoretically 
creates an enforceable right, the continuing federal prohibition operates as a 
substantial impediment to the enforcement of that right and to the possibility 
of a remedy.”213 
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 While there is some debate between practitioners and academics on 
the effectiveness of certain patents in aiding innovation, patents are typically 
seen as beneficial in technological growth.214 This has been reaffirmed by 
some through assertions that “[more] patents materially spur [more] 
innovation”215 and that “technological innovation and economic growth” are 
undercut when patent filings diminish.216 Broadly, this can be summed up by 
the policy stance that “more patents equals more innovation.”217 
Additionally, the chilling of these patent filings—especially in the growing 
marijuana industry—can undermine the invention of potentially ground-
breaking innovations, which commonly arise from newer companies.218 
Although it is clear that the rate of individual patenting has 
been decreasing in the United States over time, it is widely 
believed that individuals and small entities have an important 
impact on the innovation ecosystem--perhaps an outsized 
impact. This is for several reasons. First, there is some 
evidence that the inventions from smaller entities are more 
likely to be disruptive in nature, moving the pace of 
technological change forward. Second, in some industries, 
such as high technology and pharmaceuticals, small 
companies and individuals serve as important innovation 
inputs into larger, established companies.219 
Due to the risk of federal prosecution, and the unknowingness as to the full 
benefits afforded to a marijuana-related patent, these small entities and 
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individuals are likely hesitant to publicly share their research and marijuana 
use through the patent system. Thus it appears that this chilling effect on 
marijuana-related patents is depriving the public important research. 
Important research that can create market competition and potentially 
ground-breaking innovations. The public will continue to be deprived of this 
research and innovation unless something changes in the current federal 
scheme. 
CONCLUSION 
 By their very nature, patents are exclusionary. A patent grants the 
right to exclude others from making use of an invention or process. But 
patents are also tools to promote innovation. However, when an invalid patent 
is granted, the patent becomes an exclusionary tool that also chills innovation. 
UCANN’s ‘911 Patent is an invalid patent that is chilling innovation in the 
cannabis market—specifically in the liquid CBD market. By invalidating the 
‘911 Patent, the federal courts can help to promote innovation once again. 
But the ‘911 Patent is not the only thing hindering innovation in the cannabis 
market. While the Controlled Substances Act continues to prohibit cannabis 
at a federal level, researchers and medical professionals will be unsure of the 
legality of their actions. This naturally leads to another chilling effect in the 
use of cannabis in the medical field and within research firms. By amending 
the Controlled Substances Act to allow cannabis for medical and research 
purposes, and allowing states to opt out of the Act, the federal government 
can help to promote innovation in the cannabis market. This approach could 
eliminate the gaps in cannabis research and knowledge that continue to 
plague the U.S. to this day. 
